Smart niosomes of temozolomide for enhancement of brain targeting

De, Anindita; Venkatesh, Nagasamy; Senthil, M; Sanapalli, Bharat Kumar Reddy; R, Shanmugham; Karri, Veera Venkata Satyanarayana Reddy

doi:10.1177/1849543518805355

Cited by 56 publications

(31 citation statements)

References 33 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been shown that surface modification of the niosomes promotes the target specificity for the cancer drug delivery system. For instance, modification of temozolomide-loaded niosomes with chlorotoxin, a target-specific peptide, significantly enhanced the gliomas targeting efficiency of the temozolomide [59]. A study reported that surface modified niosomes containing olanzapine (an atypical antipsychotic drug) showed a 3-fold increase in olanzapine concentration in the brain compared to the intranasal solution of the drug [60].…”

Section: Niosomesmentioning

confidence: 99%

Intranasal Delivery of Nanoformulations: A Potential Way of Treatment for Neurological Disorders

et al. 2020

View full text Add to dashboard Cite

Although the global prevalence of neurological disorders such as Parkinson's disease, Alzheimer's disease, glioblastoma, epilepsy, and multiple sclerosis is steadily increasing, effective delivery of drug molecules in therapeutic quantities to the central nervous system (CNS) is still lacking. The blood brain barrier (BBB) is the major obstacle for the entry of drugs into the brain, as it comprises a tight layer of endothelial cells surrounded by astrocyte foot processes that limit drugs' entry. In recent times, intranasal drug delivery has emerged as a reliable method to bypass the BBB and treat neurological diseases. The intranasal route for drug delivery to the brain with both solution and particulate formulations has been demonstrated repeatedly in preclinical models, including in human trials. The key features determining the efficacy of drug delivery via the intranasal route include delivery to the olfactory area of the nares, a longer retention time at the nasal mucosal surface, enhanced penetration of the drugs through the nasal epithelia, and reduced drug metabolism in the nasal cavity. This review describes important neurological disorders, challenges in drug delivery to the disordered CNS, and new nasal delivery techniques designed to overcome these challenges and facilitate more efficient and targeted drug delivery. The potential for treatment possibilities with intranasal transfer of drugs will increase with the development of more effective formulations and delivery devices. Figure 1. Schematic demonstrating various transport systems that shuttle molecules across the BBB. Very small amount of water-soluble compounds cross through the tight junctions (paracellular), whereas lipid-soluble agents traverse via the transcellular lipophilic pathway. Selective transport systems exist for glucose, amino acids, nucleosides, and other substances, in addition to specific receptor-mediated endocytosis for certain proteins such as insulin and transferrin. (AZT = azathioprine). List of CNS Diseases Parkinson's Disease (PD)PD, occurring primarily in the substantia nigra, is the second-most common neurodegenerative disease, leading to the development of bradykinesia and tremors of cardinal motor functions ( Figure 2) [3]. PD models specifically show a decrease in dopamine transporters, which are responsible for dopamine uptake by dopaminergic neurons and progression of neuronal communications. Reduced Figure 1. Schematic demonstrating various transport systems that shuttle molecules across the BBB. Very small amount of water-soluble compounds cross through the tight junctions (paracellular), whereas lipid-soluble agents traverse via the transcellular lipophilic pathway. Selective transport systems exist for glucose, amino acids, nucleosides, and other substances, in addition to specific receptor-mediated endocytosis for certain proteins such as insulin and transferrin. (AZT = azathioprine). List of CNS Diseases Parkinson's Disease (PD)PD, occurring primarily in the substantia nigra, is the second-most common neuro...

show abstract

Section: Niosomesmentioning

confidence: 99%

Intranasal Delivery of Nanoformulations: A Potential Way of Treatment for Neurological Disorders

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In addition, drug delivery systems enhance the radiation effect of radioisotopes due to distance between radioisotope and NPs. Gholami et al showed the effect of Feraheme Ò NPs on the radiation damage of different types of radioisotopes, including 213 Bi, 223 Ra, 90 Y, 177 Lu, and 67 Cu by the use of computational modeling. They demonstrated not only radio-enhancement for internal RT by use of NPs, but also the strongest interaction with 20 nm inter-NP distance.…”

Section: Drug Delivery Systemsmentioning

confidence: 99%

“…11 In addition, SIR-Spheres Ò , 90 Y-labeled resin microspheres, are approved by FDA for the treatment of unresectable hepatocellular carcinoma. 12 Zevalin Ò , 90 Y-labeled form of ibritumomab tiuxetan, and Bexxar Ò , 131 I-labeled form of tositumomab, are used for the treatment of lymphoma. 13 These b --emitting radiopharmaceuticals are not commonly applied to the patients because of economic and logistic problems.…”

Section: Introductionmentioning

confidence: 99%

Targeted Alpha Therapy and Nanocarrier Approach

Silindir-Gunay

Karpuz

Özer

2020

Cancer Biotherapy and Radiopharmaceuticals

View full text Add to dashboard Cite

The rates of cancer incidence and mortality are increasing day by day. Although several conventional methods including surgery, chemotherapy, and radiotherapy (RT) exist for cancer treatment, they are insufficient in the eradication of all tumor tissues and have some side-effects such as narrow therapeutic index and serious sideeffects to healthy tissues. Moreover, it may probably recur in time due to the survival and spreading of cancerous cells or any possible metastases. Targeted radionuclide therapy is a promising alternative. a particles are ideal for localized cell killing because of their high linear energy transfer and short ranges. However, upon emission of a particles, the daughter nuclides induce a recoil energy to lead decoupling from any chemical bond that may accumulate in normal tissues. Targeted a therapy can also be performed by targeted delivery systems apart from mAb, mAb fragments, peptides, and small molecules for selective tumor therapy. Targeted drug delivery systems have been developed to overcome the limitations of a therapy. Moreover, drug delivery systems are one of the most searched applications in cancer imaging and/or treatment due to their targeting ability to tumor or biocompatibility properties. The aim of this article is to summarize tumor therapy applications, targeted a RT approach, and to review the role of drug delivery systems in the delivery of a particles for cancer therapy and some instances of targeted a-emitting drug delivery systems from the literature.

show abstract

“…Among various techniques of niosomal formation, thin-film hydration technique is widely used because it is simpler than the others. The examples of success studies by using the technique are the niosomes entrapped with temozolomide 22 , etoricoxib 23 , stavudine 24 , cefixime 25 , and piroxicam 26 . However, niosomes formed by the technique are multi-lamellar vesicles (MLVs) 27,28 .…”

Section: Fig 1: Distribution Of Particle Sizes Of Each Niosome Formumentioning

confidence: 99%

Untitled

2020

IJPSR

View full text Add to dashboard Cite

Niosome is one of the synthetic nanoparticles which often is used for drug delivery and cosmetic industry. The aim of this study was to prepare niosomes encapsulated with KT2 and RT2. KT2 and RT2 are antimicrobial and anticancer peptides derived from crocodile leukocyte extract. Niosomes encapsulated with KT2 and RT2 were prepared by thinfilm hydration technique, and peptide encapsulation efficiency was evaluated. Niosome particle size, size distribution, and surface morphology were also studied. The results show that KT2 and RT2 were successfully loaded in the formulations with encapsulation efficiencies of 70.9 ± 0.9% and 59.6 ± 3.4%, respectively. The mean particle size and zeta potential of KT2 and RT2 encapsulated niosomes were 9.3 ± 1.13 µm and-57.39 ± 2.53 mV and 9.1 ± 0.03 µm and-50.91 ± 2.28 mV, respectively. Niosomes had spherical shapes with rough surfaces. Niosomes coated with hydroxypropyl methylcellulose phthalate (HPMCP) were evaluated for pH stability. At pH 1.2 and 4.5, the peptide-encapsulated niosomes were stable. In conclusion, these peptide-encapsulated niosomes have high potential for therapeutic, cosmetic and beauty product applications.

show abstract

Smart niosomes of temozolomide for enhancement of brain targeting

Cited by 56 publications

References 33 publications

Intranasal Delivery of Nanoformulations: A Potential Way of Treatment for Neurological Disorders

Intranasal Delivery of Nanoformulations: A Potential Way of Treatment for Neurological Disorders

Targeted Alpha Therapy and Nanocarrier Approach

Untitled

Contact Info

Product

Resources

About